Compare SOWG & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOWG | CVRX |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 81.3M |
| IPO Year | 2011 | 2021 |
| Metric | SOWG | CVRX |
|---|---|---|
| Price | $2.90 | $2.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 16.2K | ★ 658.9K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $0.10 | $2.20 |
| 52 Week High | $4.45 | $11.30 |
| Indicator | SOWG | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 41.35 |
| Support Level | $2.45 | $2.70 |
| Resistance Level | $3.65 | $3.24 |
| Average True Range (ATR) | 0.39 | 0.18 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 11.60 | 54.74 |
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.